GENE ONLINE|News &
Opinion
Blog

2022-03-08| Asia-Pacific

HCmed and Formosa Laboratories Join Forces to Create CDMO for Inhaled Drugs

by Joy Lin
Share To

The global inhalation drug market was estimated to have reached $25 billion in 2020. The COVID-19 pandemic has further driven demand and development of treatments for respiratory diseases. 

To address demand, Taiwan-based medical device maker HCmed has announced that it is joining forces with Formosa Laboratories and its wholly-owned subsidiary Formosa Pharmaceuticals to create a global contract development and manufacturing organization (CDMO). The entity will integrate HCmed’s vibrating mesh nebulizers, Formosa Lab’s drug development and manufacturing and Formosa Pharma’s nanotechnology platform. 

HCmed believes that CDMOs cannot simply provide partners with a platform to deliver drugs. According to HCmed CEO Jason Cheng, CDMOs should also offer “integrated services that extend to drug development, mass production, product packaging.”

“Through these services, the combination product development time can be shortened, and costs can be reduced,” said Cheng. 

Related Article: The 8 Companies Propelling Taiwan’s Biopharma Industry

 

Combining Technologies and Expertise

 

Of the various drug administration methods, inhaled delivery comes with the advantages of improved dosing and patient adherence. It is also less invasive compared to injections. 

HCmed specializes in developing vibrating mesh nebulizers. These devices turn therapeutic drugs such as small molecules and biologics into aerosol form for optimal delivery. 

Formosa Labs, through its subsidiary Formosa Pharma, develops new drugs targeting the fields of ophthalmology, oncology, analgesics and infection. 

The drugs are developed using Activus Pure Nanoparticle Technology (APNT), which Formosa Pharma acquired from Japan-based Activus Pharma for $3.5 million upfront in 2017. APNT allows active pharmaceutical ingredients to be grinded down to the 50-300nm range. 

A candidate developed through APNT is currently in a Phase 3 trial in the US for inflammation and pain after eye surgery. 

Together, the three companies aim to build a one-stop service for the development process, including early drug development, clinical trial management, mass production, and product launch.

Related Article: How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Taiwanese Hospitals Make Strong Showing in “World’s Best Hospitals” Ranking
2024-03-12
JPM 2024: Taiwan’s Pharma Giant Bora Pharmaceuticals Climbing US Pharmaceutical Summit
2024-01-10
LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top